Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer

This study is testing a combination treatment — radiation therapy plus chemotherapy (SOX), an anti-angiogenic drug (apatinib), and an immunotherapy drug (camrelizumab) — given before and after surgery for locally advanced stomach or gastroesophageal junction cancer. **You may be eligible if...** - You have locally advanced stomach or GEJ cancer (stage T3–T4N+M0) that has not yet been treated - You are planning to have surgery following pre-operative treatment - You are in good health (ECOG 0–1) with adequate organ function - Your life expectancy is greater than 12 months - You are willing to use contraception during and after treatment **You may NOT be eligible if...** - You have uncontrolled high blood pressure despite medication - You have a known allergy to any of the study drugs - You have a bleeding disorder or blood-clotting problem - You have congenital or acquired immune deficiency (such as HIV) Talk to your doctor to see if this trial is right for you.